Activation of Inflammatory Mediators in Heart Failure

Heart Failure

Volumn , Issue , 2011, Pages 163-184

  Mann, Douglas L ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884441362     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5895-3.10011-7     Document Type: Chapter

References (125)

1. Lower R. Tractatus de corde: de motu & colore sagnuinus et chyli in eum tranfitu 1669, Jacobi Alleftry, London.
2. Levine B., Kalman J., Mayer L., et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990, 223:236-241.
3. Wiley S.R., Winkles J.A. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 2003, 14:241-249.
4. Pomerantz B.J., Reznikov L.L., Harken A.H., et al. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci U S A 2001, 98:2871-2876.
5. Sanada S., Hakuno D., Higgins L.J., et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007, 117:1538-1549.
6. Gulick T.S., Chung M.K., Pieper S.J., et al. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness. Proc Natl Acad Sci U S A 1989, 86:6753-6757.
7. Torre-Amione G., Kapadia S., Lee J., et al. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995, 92:1487-1493.
8. Torre-Amione G., Kapadia S., Lee J., et al. Tumor necrosis factorα and tumor necrosis factor receptors in the failing human heart. Circulation 1996, 93:704-711.
9. Ramani R., Mathier M., Wang P., et al. Inhibition of tumor necrosis factor receptor-1-mediated pathways has beneficial effects in a murine model of postischemic remodeling. Am J Physiol Heart Circ Physiol 2004, 287:H1369-H1377.
10. Olsson I., Lantz M., Nilsson E., et al. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 1989, 42:270-275.
11. Deswal A., Petersen N.J., Feldman A.M., et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the vesnarinone trial (VEST). Circulation 2001, 103:2055-2059.
12. Chorianopoulos E., Heger T., Lutz M., et al. FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK. Basic Res Cardiol 105; 301-313 2010.
13. Jain M., Jakubowski A., Cui L., et al. A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation 2009, 119:2058-2068.
14. Dinarello C.A. Biological basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
15. Francis S.E., Holden H., Holt C.M., et al. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol 1998, 30:215-223.
16. Dinarello C.A. Interleukin-1. The cytokine handbook 1991, Academic Press, Boston. A. Thomson (Ed.).
17. Dinarello C.A. Interleukin-18. Methods 1999, 19:121-132.
18. Raeburn C.D., Dinarello C.A., Zimmerman M.A., et al. Neutralization of IL-18 attenuates lipopolysaccharide-induced myocardial dysfunction. Am J Physiol Heart Circ Physiol 2002, 283:H650-H657.
19. Born T.L., Thomassen E., Bird T.A., et al. Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J Biol Chem 1998, 273:29445-29450.
20. Kakkar R., Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008, 7:827-840.
21. Sabatine M.S., Morrow D.A., Higgins L.J., et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008, 117:1936-1944.
22. Hirano T. Interleukin-6. The cytokine handbook 1991, Academic Press, Boston. A. Thomson (Ed.).
23. Hirano T., Yasukawa K., Harada H., et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986, 324:73-78.
24. Finkel M.S., Hoffman R.A., Shen L., et al. Interleukin-6 (IL-6) as a mediator of stunned myocardium. Am J Cardiol 1993, 71:1231-1232.
25. Sehgal P.B. Interleukin-6 type cytokines in vivo: regulated bioavailability. Proc Soc Exp Biol Med 1996, 213:238-247.
26. Eiken H.G., Oie E., Damas J.K., et al. Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure. Eur J Clin Invest 2001, 31:389-397.
27. Talwar S., Squire I.B., Downie P.F., et al. Elevated circulating cardiotrophin-1 in heart failure: relationship with parameters of left ventricular systolic dysfunction. Clin Sci (Lond) 2000, 99:83-88.
28. Hirota H., Yoshida K., Kishimoto T., et al. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A 1995, 92:4862-4866.
29. Yoshida K., Taga T., Saito M., et al. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci U S A 1996, 93:407-411.
30. Aukrust P., Ueland T., Muller F., et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998, 97:1136-1143.
31. Frantz S., Ertl G., Bauersachs J. Toll-like receptor signaling in the ischemic heart. Front Biosci 2008, 13:5772-5779.
32. Chao W. Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. Am J Physiol Heart Circ Physiol 2009, 296:H1-H12.
33. Mann D.L. Tumor necrosis factor and viral myocarditis: the fine line between innate and inappropriate immune responses in the heart. Circulation 2001, 103:626-629.
34. Cowan D.B., Poutias D.N., del Nido P.J., et al. CD14-independent activation of cardiomyocyte signal transduction by bacterial endotoxin. Am J Physiol Heart Circ Physiol 2000, 279:H619-H629.
35. Frantz S., Kelly R.A., Bourcier T. Role of TLR-2 in the activation of nuclear factor-kappa B by oxidative stress in cardiac myocytes. J Biol Chem 2001, 276:5197-5203.
36. Li M., Carpio D.F., Zheng Y., et al. An essential role of the NF-kappa B/toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol 2001, 166:7128-7135.
37. Frantz S., Kobzik L., Kim Y.D., et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 1999, 104:271-280.
38. Baumgarten G., Knuefermann P., Nozaki N., et al. In vivo expression of proinflammatory mediators in the adult heart after endotoxin administration: the role of toll-like receptor-4. J Infect Dis 2001, 183:1617-1624.
39. Nemoto S., Vallejo J.G., Knuefermann P., et al. Escherichia coli lipopolysaccharide-induced left ventricular dysfunction: the role of toll-like receptor-4 in the adult mammalian heart. Am J Physiol 2002, 282:H2316-H2323.
40. Knuefermann P., Nemoto S., Misra A., et al. CD14-deficient mice are protected against lipopolysaccharide-induced cardiac inflammation and left ventricular dysfunction. Circulation 2002, 106:2608-2615.
41. Sakata Y., Dong J.W., Vallejo J.G., et al. Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2007, 292:H503-H509.
42. Oyama J., Blais C., Liu X., et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004, 109:784-789.
43. Shishido T., Nozaki N., Yamaguchi S., et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 2003, 108:2905-2910.
44. Riad A., Jager S., Sobirey M., et al. Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. J Immunol 2008, 180:6954-6961.
45. Bozkurt B., Kribbs S., Clubb F.J., et al. Pathophysiologically relevant concentrations of tumor necrosis factorα promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998, 97:1382-1391.
46. Seta Y., Shan K., Bozkurt B., et al. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 1996, 2:243-249.
47. Tracey K.J., Beutler B., Lowry S.F., et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986, 234:470-474.
48. Natanson C., Eichenholz P.W., Danner R.L., et al. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 1989, 169:823-832.
49. Kubota T., McTiernan C.F., Frye C.S., et al. Dilated cardiomyopathy in transgenic mice with cardiac specific overexpression of tumor necrosis factor-alpha. Circ Res 1997, 81:627-635.
50. Franco F., Thomas G.D., Giroir B.P., et al. Magnetic resonance imaging and invasive evaluation of development of heart failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1999, 99:448-454.
51. Yokoyama T., Vaca L., Rossen R.D., et al. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993, 92:2303-2312.
52. Oral H., Dorn G.W., Mann D.L. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte. J Biol Chem 1997, 272:4836-4842.
53. Balligand J.L., Ungureanu D., Kelly R.A., et al. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest 1993, 91:2314-2319.
54. Mallat Z., Heymes C., Corbaz A., et al. Evidence for altered interleukin 18 (IL)-18 pathway in human heart failure. FASEB J 2004, 18:1752-1754.
55. 2+-independent nitric oxide synthase in the myocardium. Brit J Pharmacol 1992, 105:575-580.
56. Balligand J.L., Kelly R.A., Marsden P.A., et al. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci U S A 1993, 90:347-351.
57. De Belder A.J., Radomski M.W., Why H.J.F., et al. Nitric oxide synthase activities in human myocardium. Lancet 1993, 341:84-86.
58. Kelly R.A., Ballingand J.L., Smith T.W. Nitric oxide and cardiac function. Circ Res 1996, 79:363-380.
59. Rosenkranz-Weiss P., Sessa W.C., Milstien S., et al. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. J Clin Invest 1994, 223:2236-2243.
60. Roberts A.B., Vodovotz Y., Roche N.S., et al. Role of nitric oxide in antagonistic effects of transforming growth factor-b and interleukin-1b on the beating rate of cultured myocytes. Mol Endocrinol 1992, 6:1921-1930.
61. Stuehr D.J., Cho H.J., Kwon N.S., et al. Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD- and FMN-containing flavoprotein. Proc Natl Acad Sci U S A 1991, 88:7773-7777.
62. 2+ current. J Biol Chem 1993, 268:26286-26295.
63. Shah A.M., Lewis M.J., Henderson A.H. Effects of 8-bromo-GMP on contraction and on inotropic response of ferret cardiac muscle. J Mol Cell Cardiol 1991, 23:55-64.
64. Finkel M.S., Oddis C.V., Jacob T.D., et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992, 257:387-389.
65. Kolesnick R.N. Sphingomyelin and derivatives as cellular signals. Prog Lipid Res 1991, 30:1-38.
66. Sabbadini R.A., Mcnutt W., Jenkins G., et al. Sphingosine is endogenous to cardiac and skeletal muscle. Biochem Biophys Res Commun 1993, 193:752-758.
67. Sabbadini R.A., Betto R., Teresi A., et al. The effects of sphingosine on sarcoplasmic reticulum membrane calcium release. J Biol Chem 1992, 267:15475-15484.
68. Yokoyama T., Nakano M., Bednarczyk J.L., et al. Tumor necrosis factorα provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997, 95:1247-1252.
69. Sivasubramanian N., Coker M.L., Kurrelmeyer K., et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2001, 104:826-831.
70. Krown K.A., Page M.T., Nguyen C., et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996, 98:2854-2865.
71. Bryant D., Becker L., Richardson J., et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factorα (TNF). Circulation 1998, 97:1375-1381.
72. Weber K.T. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 1989, 13(7):1637-1652.
73. Engel D., Peshock R., Armstrong R.C., et al. Cardiac myocyte apoptosis provokes adverse cardiac remodeling in transgenic mice with targeted TNF overexpression. Am J Physiol Heart Circ Physiol 2004, 287:H1303-H1311.
74. Haudek S.B., Taffet G.E., Schneider M.D., et al. TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. J Clin Invest 2007, 117:2692-2701.
75. Abbate A., Salloum F.N., Vecile E., et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008, 117:2670-2683.
76. Dostal D.E., Baker K.M. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function?. Circ Res 1999, 85:643-650.
77. Brasier A.R., Jamaluddin M., Han Y., et al. Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor. Mol Cell Biochem 2000, 212:155-169.
78. Luft F.C. Workshop: mechanisms and cardiovascular damage in hypertension. Hypertension 2001, 37:594-598.
79. Kalra D., Baumgarten G., Dibbs Z., et al. Nitric oxide provokes tumor necrosis factor-alpha expression in adult feline myocardium through a cgmp-dependent pathway. Circulation 2000, 102:1302-1307.
80. Flesch M., Hoper A., Dell'Italia L., et al. Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2003, 108:598-604.
81. Ferrari R., Bachetti T., Confortini R., et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive failure. Circulation 1995, 92:1479-1486.
82. Anker S.D., Volterrnani M., Egerer K.R., et al. TNFα as predictor of peak leg blood flow in chronic heart failure. Q J Med 1998, 91:199-203.
83. Fichtlscherer S., Rossig L., Breuer S., et al. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 2001, 104:3023-3025.
84. Zabel P., Schade F.U., Schlaak M. Inhibition of endogenous TNF formation by pentoxifylline. Immunbiol 1993, 187:447-463.
85. Sliwa K., Skudicky D., Candy G., et al. Randomized investigation of effects of pentoxifylline on left ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998, 351:1091-1093.
86. Skudicky D., Bergemann A., Sliwa K., et al. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation 2001, 103:1083-1088.
87. Sliwa K., Woodiwiss A., Candy G., et al. Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 2002, 90:1118-1122.
88. Sliwa K., Woodiwiss A., Kone V.N., et al. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation 2004, 109:750-755.
89. Skudicky D., Sliwa K., Bergemann A., et al. Reduction in Fas/APO-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxifylline. Heart 2000, 84:438-439.
90. Sampaio E.P., Sarno E.N., Galilly R., et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991, 173:699-703.
91. Moreira A.L., Sampaio E.P., Zmuidzinas A., et al. Thalidomide exerts its inhibitory action on tumor necrosis factor-alpha by enhancing messenger RNA degradation. J Exp Med 1993, 177:1675-1680.
92. Agoston I., Dibbs Z.I., Wang F., et al. Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. J Card Fail 2002, 8:306-314.
93. Gullestad L., Ueland T., Fjeld J.G., et al. Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. Circulation 2005, 112:3408-3414.
94. Remick D.G., Strieter R.M., Lynch I.J.P., et al. In vivo dynamics of murine tumor necrosis factorα gene expression. Kinetics of dexamethasone-induced suppression. Lab Invest 1989, 60:766-771.
95. Parrillo J.E., Cunnion R.E., Epstein S.E., et al. A prospective randomized controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989, 321:1061-1068.
96. Kapadia S., Torre-Amione G., Yokoyama T., et al. Soluble tumor necrosis factor binding proteins modulate the negative inotropic effects of TNFα in vitro. Am J Physiol 1995, 37:H517-H525.
97. Deswal A., Bozkurt B., Seta Y., et al. A phase I trial of tumor necrosis factor receptor (p75) fusion protein (TNFR: Fc) in patients with advanced heart failure. Circulation 1999, 99:3224-3226.
98. Bozkurt B., Torre-Amione G., Warren M.S., et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001, 103:1044-1047.
99. Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail 2001, 7:176-182.
100. Mann D.L., McMurray J.J.V., Packer M., et al. Targeted anti-cytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation 2004, 109:1594-1602.
101. Chung E.S., Packer M., Lo K.H., et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-(alpha), in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 2003, 107:3133-3140.
102. Homeister J.W., Lucchesi B.R. Complement activation and inhibition in myocardial ischemia and reperfusion injury. Annu Rev Pharmacol Toxicol 1994, 34:17-40.
103. Klein B., Brailly H. Cytokine-binding proteins: stimulating antagonists. Immunol Today 1995, 16:216-220.
104. Mann D.L., Bozkurt B., Torre-Amione G., et al. Effect of the soluble TNF-antagonist etanercept on tumor necrosis factor bioactivity and stability. Clin Transl Sci 2008, 1:142-145.
105. Frishman J.I., Edwards C.K., Sonnenberg M.G., et al. Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors. J Infect Dis 2000, 182:1722-1730.
106. Maury C.P., Teppo A.M. Cachectin/tumour necrosis factor-alpha in the circulation of patients with rheumatic disease. Int J Tissue React 1989, 11:189-193.
107. Aukrust P., Yndestad A., Damas J.K., et al. Potential mechanisms of benefit with thalidomide in chronic heart failure. Am J Cardiovasc Drugs 2007, 7:127-134.
108. Gullestad L., Aass H., Fjeld J.G., et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001, 103:220-225.
109. McNamara D.M., Holubkov R., Starling R.C., et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001, 103:2254-2259.
110. Fadok V.A., Bratton D.L., Konowal A., et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998, 101:890-898.
111. Babaei S., Stewart D.J., Picard P., et al. Effects of VasoCare therapy on the initiation and progression of atherosclerosis. Atherosclerosis 2002, 162:45-53.
112. Aukrust P., Ueland T., Lien E., et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999, 83:376-382.
113. Torre-Amione G., Sestier F., Radovancevic B., et al. Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial. J Am Coll Cardiol 2004, 44:1181-1186.
114. Torre-Amione G., Anker S.D., Bourge R.C., et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet 2008, 371:228-236.
115. Ramasubbu K., Mann D.L. The emerging role of statins in the treatment of heart failure. J Am Coll Cardiol 2006, 47:342-344.
116. Khush K.K., Waters D.D., Bittner V., et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the treating to new targets (TNT) study. Circulation 2007, 115:576-583.
117. Ramasubbu K., Estep J., White D.L., et al. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008, 51:415-426.
118. Krum H., Ashton E., Reid C., et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 2007, 13:1-7.
119. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248-2261.
120. Gissi H.F. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1231-1239. Investigators.
121. Gissi H.F. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223-1230. Investigators.
122. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002, 91:988-998.
123. Heymans S., Hirsch E., Anker S.D., et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the translational research committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009, 11:119-129.
124. Weinberger S.R., Morris T.S., Pawlak M. Recent trends in protein biochip technology. Pharmacogenomics 2000, 1:395-416.
125. Gordon S. Pattern recognition receptors. Doubling up for the innate immune response. Cell 2002, 111:927-930.